Investors sold shares of Thermo Fisher Scientific Inc (NYSE:TMO) on strength during trading on Thursday. $104.76 million flowed into the stock on the tick-up and $177.70 million flowed out of the stock on the tick-down, for a money net flow of $72.94 million out of the stock. Of all stocks tracked, Thermo Fisher Scientific had the 7th highest net out-flow for the day. Thermo Fisher Scientific traded up $0.70 for the day and closed at $200.37
Several equities analysts recently issued reports on the company. Deutsche Bank AG set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Leerink Swann raised their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Cowen and Company restated an “outperform” rating and set a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Finally, Barclays PLC restated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $205.50.
The firm has a market cap of $78.17 billion, a P/E ratio of 34.91 and a beta of 1.05. The company’s 50-day moving average price is $191.38 and its 200 day moving average price is $177.67.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 earnings per share. On average, equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.
In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at $3,657,490.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now directly owns 25,518 shares in the company, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. In the last three months, insiders sold 52,738 shares of company stock worth $9,302,112. Insiders own 0.49% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Honeywell International Inc. boosted its stake in Thermo Fisher Scientific by 34.6% in the third quarter. Honeywell International Inc. now owns 194,900 shares of the medical research company’s stock worth $36,875,000 after purchasing an additional 50,100 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Thermo Fisher Scientific by 13.9% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 38,242 shares of the medical research company’s stock worth $7,236,000 after purchasing an additional 4,661 shares in the last quarter. Calamos Advisors LLC boosted its stake in Thermo Fisher Scientific by 1.6% in the third quarter. Calamos Advisors LLC now owns 147,264 shares of the medical research company’s stock worth $27,862,000 after purchasing an additional 2,267 shares in the last quarter. Rothschild Investment Corp IL boosted its stake in Thermo Fisher Scientific by 0.5% in the third quarter. Rothschild Investment Corp IL now owns 70,523 shares of the medical research company’s stock worth $13,343,000 after purchasing an additional 341 shares in the last quarter. Finally, Liberty Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 2.1% in the third quarter. Liberty Capital Management Inc. now owns 19,579 shares of the medical research company’s stock worth $3,795,000 after purchasing an additional 411 shares in the last quarter. 83.47% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/27/investors-sell-thermo-fisher-scientific-inc-tmo-on-strength-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.